Drug delivery to the suprachoroidal space

Sung Won Cho, Timothy Olsen

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Age-related macular degeneration (AMD), retinal vascular disease, and diabetic macular edema (DME) represent leading causes of vision loss from diseases that affect the posterior segment of the eye in developed countries (Augustin and Offermann 2006; Campbell et al. 2010; DRCR Network et al. 2009, 2010; Ip et al. 2009; Nomoto et al. 2009; Ramchandran et al. 2008; Soheilian et al. 2009; Stahl et al. 2007). Other posterior segment disorders, such as uveitis, retinitis pigmentosa (RP), and optic nerve disease, also represent potentially treatable forms of blindness that involve disease processes that affect the posterior segment tissues of the eye, including the retina, choroid, and optic nerve (Cai et al. 2010; Giansanti et al. 2008; Gilger et al. 2010; Jacobson and Cideciyan 2010; Janoria et al. 2010; Kanamori et al. 2010). Administration or delivery of a specific drug to posterior segment tissues has gained significant attention in research and represents an important area of investigation. Our goal is to develop effective, targeted, and local delivery for the treatment of posterior segment diseases that affect vision. Recently, pharmaceutical innovation and development has produced new drugs for the treatment of the posterior segment, and novel drug delivery technologies are under investigation. Delivering drugs to the suprachoroidal space, a potential space between the choroid and the sclera, will be discussed and represents a new space that is gaining attention for novel drug delivery technology.

Original languageEnglish (US)
Title of host publicationOcular Drug Delivery Systems
Subtitle of host publicationBarriers and Application of Nanoparticulate Systems
PublisherCRC Press
Pages235-258
Number of pages24
ISBN (Electronic)9781439848012
ISBN (Print)9781439848005
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

Drug delivery
Posterior Eye Segment
Pharmaceutical Preparations
Choroid
Optics
Tissue
Technology
Retinal Diseases
Retinal Vessels
Optic Nerve Diseases
Sclera
Retinitis Pigmentosa
Macular Edema
Uveitis
Macular Degeneration
Blindness
Optic Nerve
Vascular Diseases
Developed Countries
Innovation

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Cho, S. W., & Olsen, T. (2012). Drug delivery to the suprachoroidal space. In Ocular Drug Delivery Systems: Barriers and Application of Nanoparticulate Systems (pp. 235-258). CRC Press. https://doi.org/10.1201/b12950

Drug delivery to the suprachoroidal space. / Cho, Sung Won; Olsen, Timothy.

Ocular Drug Delivery Systems: Barriers and Application of Nanoparticulate Systems. CRC Press, 2012. p. 235-258.

Research output: Chapter in Book/Report/Conference proceedingChapter

Cho, SW & Olsen, T 2012, Drug delivery to the suprachoroidal space. in Ocular Drug Delivery Systems: Barriers and Application of Nanoparticulate Systems. CRC Press, pp. 235-258. https://doi.org/10.1201/b12950
Cho SW, Olsen T. Drug delivery to the suprachoroidal space. In Ocular Drug Delivery Systems: Barriers and Application of Nanoparticulate Systems. CRC Press. 2012. p. 235-258 https://doi.org/10.1201/b12950
Cho, Sung Won ; Olsen, Timothy. / Drug delivery to the suprachoroidal space. Ocular Drug Delivery Systems: Barriers and Application of Nanoparticulate Systems. CRC Press, 2012. pp. 235-258
@inbook{c85c273a66304df6bb36af956315a131,
title = "Drug delivery to the suprachoroidal space",
abstract = "Age-related macular degeneration (AMD), retinal vascular disease, and diabetic macular edema (DME) represent leading causes of vision loss from diseases that affect the posterior segment of the eye in developed countries (Augustin and Offermann 2006; Campbell et al. 2010; DRCR Network et al. 2009, 2010; Ip et al. 2009; Nomoto et al. 2009; Ramchandran et al. 2008; Soheilian et al. 2009; Stahl et al. 2007). Other posterior segment disorders, such as uveitis, retinitis pigmentosa (RP), and optic nerve disease, also represent potentially treatable forms of blindness that involve disease processes that affect the posterior segment tissues of the eye, including the retina, choroid, and optic nerve (Cai et al. 2010; Giansanti et al. 2008; Gilger et al. 2010; Jacobson and Cideciyan 2010; Janoria et al. 2010; Kanamori et al. 2010). Administration or delivery of a specific drug to posterior segment tissues has gained significant attention in research and represents an important area of investigation. Our goal is to develop effective, targeted, and local delivery for the treatment of posterior segment diseases that affect vision. Recently, pharmaceutical innovation and development has produced new drugs for the treatment of the posterior segment, and novel drug delivery technologies are under investigation. Delivering drugs to the suprachoroidal space, a potential space between the choroid and the sclera, will be discussed and represents a new space that is gaining attention for novel drug delivery technology.",
author = "Cho, {Sung Won} and Timothy Olsen",
year = "2012",
month = "1",
day = "1",
doi = "10.1201/b12950",
language = "English (US)",
isbn = "9781439848005",
pages = "235--258",
booktitle = "Ocular Drug Delivery Systems",
publisher = "CRC Press",

}

TY - CHAP

T1 - Drug delivery to the suprachoroidal space

AU - Cho, Sung Won

AU - Olsen, Timothy

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Age-related macular degeneration (AMD), retinal vascular disease, and diabetic macular edema (DME) represent leading causes of vision loss from diseases that affect the posterior segment of the eye in developed countries (Augustin and Offermann 2006; Campbell et al. 2010; DRCR Network et al. 2009, 2010; Ip et al. 2009; Nomoto et al. 2009; Ramchandran et al. 2008; Soheilian et al. 2009; Stahl et al. 2007). Other posterior segment disorders, such as uveitis, retinitis pigmentosa (RP), and optic nerve disease, also represent potentially treatable forms of blindness that involve disease processes that affect the posterior segment tissues of the eye, including the retina, choroid, and optic nerve (Cai et al. 2010; Giansanti et al. 2008; Gilger et al. 2010; Jacobson and Cideciyan 2010; Janoria et al. 2010; Kanamori et al. 2010). Administration or delivery of a specific drug to posterior segment tissues has gained significant attention in research and represents an important area of investigation. Our goal is to develop effective, targeted, and local delivery for the treatment of posterior segment diseases that affect vision. Recently, pharmaceutical innovation and development has produced new drugs for the treatment of the posterior segment, and novel drug delivery technologies are under investigation. Delivering drugs to the suprachoroidal space, a potential space between the choroid and the sclera, will be discussed and represents a new space that is gaining attention for novel drug delivery technology.

AB - Age-related macular degeneration (AMD), retinal vascular disease, and diabetic macular edema (DME) represent leading causes of vision loss from diseases that affect the posterior segment of the eye in developed countries (Augustin and Offermann 2006; Campbell et al. 2010; DRCR Network et al. 2009, 2010; Ip et al. 2009; Nomoto et al. 2009; Ramchandran et al. 2008; Soheilian et al. 2009; Stahl et al. 2007). Other posterior segment disorders, such as uveitis, retinitis pigmentosa (RP), and optic nerve disease, also represent potentially treatable forms of blindness that involve disease processes that affect the posterior segment tissues of the eye, including the retina, choroid, and optic nerve (Cai et al. 2010; Giansanti et al. 2008; Gilger et al. 2010; Jacobson and Cideciyan 2010; Janoria et al. 2010; Kanamori et al. 2010). Administration or delivery of a specific drug to posterior segment tissues has gained significant attention in research and represents an important area of investigation. Our goal is to develop effective, targeted, and local delivery for the treatment of posterior segment diseases that affect vision. Recently, pharmaceutical innovation and development has produced new drugs for the treatment of the posterior segment, and novel drug delivery technologies are under investigation. Delivering drugs to the suprachoroidal space, a potential space between the choroid and the sclera, will be discussed and represents a new space that is gaining attention for novel drug delivery technology.

UR - http://www.scopus.com/inward/record.url?scp=84885000921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885000921&partnerID=8YFLogxK

U2 - 10.1201/b12950

DO - 10.1201/b12950

M3 - Chapter

AN - SCOPUS:84885000921

SN - 9781439848005

SP - 235

EP - 258

BT - Ocular Drug Delivery Systems

PB - CRC Press

ER -